Analytical Data
-
Gene name
COX7A2L
- Application
-
Alternative Names
COX7a-related protein Cytochrome c oxidase subunit VIIa-related protein EB1
-
Species
Human
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14548
-
Expression Region
1-114aa
-
Molecular Weight
39.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
COX7A2L, a member of the cytochrome c oxidase (COX) subunit family, plays a crucial role in mitochondrial respiration and energy production. Its involvement in the COX complex, which is the terminal enzyme of the mitochondrial electron transport chain, underscores its importance in cellular metabolism. Research into COX7A2L is motivated by its potential implications in a variety of biological processes and diseases, particularly those related to mitochondrial dysfunction. Abnormalities in COX function have been associated with neurodegenerative diseases, metabolic disorders, and ischemic conditions. As such, understanding the structure-function relationship of COX7A2L is critical for elucidating its role in these pathological states. Recombinant expression of COX7A2L facilitates detailed studies of its biochemical properties and interaction with other mitochondrial components, enabling researchers to investigate how variations in this protein may contribute to disease mechanisms. Furthermore, the generation of recombinant COX7A2L allows for potential therapeutic applications, including the development of strategies aimed at enhancing mitochondrial function in conditions resulting from oxidative stress or impaired energy metabolism. By exploring the properties and functions of this protein, researchers hope to pave the way for novel treatments targeting mitochondrial-related diseases, improving our understanding of their etiology and progression.
